Aldrich J, Canning M, Bhave M (2023) Monitoring of triple negative breast cancer after neoadjuvant chemotherapy. Clin Breast Cancer 23(8):832–834. https://doi.org/10.1016/j.clbc.2023.08.001

Article  PubMed  Google Scholar 

Atisha D, Alderman AK, Lowery JC, Kuhn LE, Davis J, Wilkins EG (2008) Prospective analysis of long-term psychosocial outcomes in breast reconstruction: two-year postoperative results from the Michigan breast reconstruction outcomes study. Ann Surg 247(6):1019–1028. https://doi.org/10.1097/SLA.0b013e3181728a5c

Atzori G, Gipponi M, Cornacchia C, Diaz R, Sparavigna M, Gallo M, Ruelle T, Murelli F, Franchelli S, Depaoli F, Friedman D, Fregatti P (2022) No ink on tumor in breast-conserving surgery after neoadjuvant chemotherapy. J Pers Med 12(7). https://doi.org/10.3390/jpm12071031

Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL, Wolmark N (2003) The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol 21(22):4165–4174. https://doi.org/10.1200/jco.2003.12.005

Article  CAS  PubMed  Google Scholar 

Boughey JC, McCall LM, Ballman KV, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Leitch AM, Flippo-Morton T, Hunt KK (2014) Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) prospective multicenter clinical trial. Ann Surg 260(4):608–614 discussion 614–606. https://doi.org/10.1097/sla.0000000000000924

Article  PubMed  Google Scholar 

Cance WG, Carey LA, Calvo BF, Sartor C, Sawyer L, Moore DT, Rosenman J, Ollila DW, Graham M 2nd (2002) Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival. Ann Surg 236(3):295–302 discussion 302–293. https://doi.org/10.1097/01.Sla.0000027526.67560.64

Chaudhary LN, Wilkinson KH, Kong A (2018) Triple-negative breast cancer: who should receive neoadjuvant chemotherapy? Surg Oncol Clin N Am 27(1):141–153. https://doi.org/10.1016/j.soc.2017.08.004

Article  PubMed  Google Scholar 

Chen AM, Meric-Bernstam F, Hunt KK, Thames HD, Oswald MJ, Outlaw ED, Strom EA, McNeese MD, Kuerer HM, Ross MI, Singletary SE, Ames FC, Feig BW, Sahin AA, Perkins GH, Schechter NR, Hortobagyi GN, Buchholz TA (2004) Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol 22(12):2303–2312. https://doi.org/10.1200/jco.2004.09.062

Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, Iwata H, Masuda N, Otero MT, Gokmen E, Loi S, Guo Z, Zhao J, Aktan G, Karantza V, Schmid P (2020) Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 396(10265):1817–1828. https://doi.org/10.1016/s0140-6736(20)32531-9

Criscitiello C, Azim HA Jr., Agbor-tarh D, de Azambuja E, Piccart M, Baselga J, Eidtmann H, Di Cosimo S, Bradbury I, Rubio IT (2013) Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial. Ann Oncol 24(8):1980–1985. https://doi.org/10.1093/annonc/mdt129

Article  CAS  PubMed  Google Scholar 

Criscitiello C, Curigliano G, Burstein HJ, Wong S, Esposito A, Viale G, Giuliano M, Veronesi U, Santangelo M, Golshan M (2016) Breast conservation following neoadjuvant therapy for breast cancer in the modern era: are we losing the opportunity? Eur J Surg Oncol 42(12):1780–1786. https://doi.org/10.1016/j.ejso.2016.10.011

Article  CAS  PubMed  Google Scholar 

Fisher CS, Margenthaler JA, Hunt KK, Schwartz T (2020) The landmark series: axillary management in breast cancer. Ann Surg Oncol 27(3):724–729. https://doi.org/10.1245/s10434-019-08154-5

Garrido-Castro AC, Lin NU, Polyak K (2019) Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov 9(2):176–198. https://doi.org/10.1158/2159-8290.Cd-18-1177

Article  CAS  PubMed  PubMed Central  Google Scholar 

Golshan M, Cirrincione CT, Sikov WM, Berry DA, Jasinski S, Weisberg TF, Somlo G, Hudis C, Winer E, Ollila DW (2015) Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance). Ann Surg 262(3):434–439 discussion 438–439. https://doi.org/10.1097/sla.0000000000001417

Gwark S, Kim HJ, Kim J, Chung IY, Kim HJ, Ko BS, Lee JW, Son BH, Ahn SH, Lee SB (2023) Survival after breast-conserving surgery compared with that after mastectomy in breast cancer patients receiving neoadjuvant chemotherapy. Ann Surg Oncol 30(5):2845–2853. https://doi.org/10.1245/s10434-022-12993-0

Article  PubMed  Google Scholar 

Hamelinck VC, Bastiaannet E, Pieterse AH, Jannink I, van de Velde CJ, Liefers GJ, Stiggelbout AM (2014) Patients’ preferences for surgical and adjuvant systemic treatment in early breast cancer: a systematic review. Cancer Treat Rev 40(8):1005–1018. https://doi.org/10.1016/j.ctrv.2014.06.007

Harbeck N, Gluz O (2017) Neoadjuvant therapy for triple negative and HER2-positive early breast cancer. Breast 34(1):S99–s103. https://doi.org/10.1016/j.breast.2017.06.038

Heneghan HM, Prichard RS, Lyons R, Regan PJ, Kelly JL, Malone C, McLaughlin R, Sweeney KJ, Kerin MJ (2011) Quality of life after immediate breast reconstruction and skin-sparing mastectomy - a comparison with patients undergoing breast conserving surgery. Eur J Surg Oncol 37(11):937–943. https://doi.org/10.1016/j.ejso.2011.08.126

Hershman D, McBride R, Jacobson JS, Lamerato L, Roberts K, Grann VR, Neugut AI (2005) Racial disparities in treatment and survival among women with early-stage breast cancer. J Clin Oncol 23(27):6639–6646. https://doi.org/10.1200/jco.2005.12.633

Article  PubMed  Google Scholar 

Killelea BK, Yang VQ, Wang SY, Hayse B, Mougalian S, Horowitz NR, Chagpar AB, Pusztai L, Lannin DR (2015) Racial differences in the use and outcome of neoadjuvant chemotherapy for breast cancer: results from the national cancer data base. J Clin Oncol 33(36):4267–4276. https://doi.org/10.1200/jco.2015.63.7801

Article  PubMed  Google Scholar 

Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26(8):1275–1281. https://doi.org/10.1200/jco.2007.14.4147

Article  PubMed  Google Scholar 

Litière S, Werutsky G, Fentiman IS, Rutgers E, Christiaens MR, Van Limbergen E, Baaijens MH, Bogaerts J, Bartelink H (2012) Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. Lancet Oncol 13(4):412–419. https://doi.org/10.1016/s1470-2045(12)70042-6

Article  PubMed  Google Scholar 

Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL (2018) Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 379(8):753–763. https://doi.org/10.1056/NEJMoa1802905

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. (2018) Lancet Oncol 19(1):27–39 https://doi.org/10.1016/s1470-2045(17)30777-5

Mamtani A, Barrio AV, King TA, Van Zee KJ, Plitas G, Pilewskie M, El-Tamer M, Gemignani ML, Heerdt AS, Sclafani LM, Sacchini V, Cody HS 3rd, Patil S, Morrow M (2016) How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study. Ann Surg Oncol 23(11):3467–3474. https://doi.org/10.1245/s10434-016-5246-8

Article  PubMed  PubMed Central  Google Scholar 

Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, Kuroi K, Im SA, Park BW, Kim SB, Yanagita Y, Ohno S, Takao S, Aogi K, Iwata H, Jeong J, Kim A, Park KH, Sasano H, Ohashi Y, Toi M (2017) Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 376(22):2147–2159. https://doi.org/10.1056/NEJMoa1612645

Article  CAS  PubMed  Google Scholar 

Masuda H, Harano K, Miura S, Wang Y, Hirota Y, Harada O, Jolly MK, Matsunaga Y, Lim B, Wood AL, Parinyanitikul N, Lee J, Gong H, George G, Levine JT, Lee H, Wang J, Lucci X, Rao A, Schweitzer A, Lawrence BL, Seitz OR, Morris RS, Hout SW, Nakamura DR, Krishnamurthy S, S., Ueno NT (2022) Changes in triple-negative breast cancer molecular subtypes in patients without pathologic complete response after neoadjuvant systemic chemotherapy. JCO Precis Oncol 6:e2000368. https://doi.org/10.1200/po.20.00368

Article  PubMed  PubMed Central  Google Scholar 

Morrow M, Jagsi R, McLeod MC, Shumway D, Katz SJ (2018) Surgeon attitudes toward the omission of axillary dissection in early breast cancer. JAMA Oncol 4(11):1511–1516. https://doi.org/10.1001/jamaoncol.2018.1908

Article  PubMed  PubMed Central  Google Scholar 

Mukhtar RA, Chau H, Woriax H, Piltin M, Ahrendt G, Tchou J, Yu H, Ding Q, Dugan CL, Sheade J, Crown A, Carr M, Wong J, Son J, Yang R, Chan T, Terando A, Alvarado M, Ewing C, Tonneson J, Tamirisa N, Gould R, Singh P, Godellas C, Larson K, Chiba A, Rao R, Sauder C, Postlewait L, Lee MC, Symmans WF, Esserman LJ, Boughey JC (2023) Breast conservation surgery and mastectomy have similar locoregional recurrence after neoadjuvant chemotherapy: results from 1462 patients on the prospective, randomized I-SPY2 trial. Ann Surg Sep 1(3):320–327. https://doi.org/10.1097/sla.0000000000005968. 278

Article  Google Scholar 

Murphy BL, Day CN, Hoskin TL, Habermann EB, Boughey JC (2018) Neoadjuvant chemotherapy use in breast cancer is greatest in excellent responders: triple-negative and HER2 + subtypes. Ann Surg Oncol 25(8):2241–2248. https://doi.org/10.1245/s10434-018-6531-5

Article  PubMed  Google Scholar 

Nathanson SD, Krag D, Kuerer HM, Newman LA, Brown M, Kerjaschki D, Pereira ER, Padera TP (2018) Breast cancer metastasis through the lympho-vascular system. Clin Exp Metastasis 35(5–6):443–454. https://doi.org/10.1007/s10585-018-9902-1

Patel SA, DeMichele A (2017) Adding adjuvant systemic treatment after neoadjuvant therapy in breast cancer: review of the data. Curr Oncol Rep 19(8):56. https://doi.org/10.1007/s11912-017-0613-6

Article  CAS  PubMed  Google Scholar 

Piltin MA, Hoskin TL, Day CN, Davis J Jr., Boughey JC (2020) Oncologic outcomes of sentinel lymph node surgery after neoadjuvant chemotherapy for node-positive breast cancer. Ann Surg Oncol 27(12):4795–4801. https://doi.org/10.1245/s10434-020-08900-0

Article  PubMed  Google Scholar 

Qiu J, Xue X, Hu C, Xu H, Kou D, Li R, Li M (2016) Comparison of clinicopathological features and prognosis in triple-negative and non-triple negative breast cancer. J Cancer 7(2):167–173. https://doi.org/10.7150/jca.10944

Article  CAS  PubMed  PubMed Central  Google Scholar 

Reyes SA, King TA, Fei K, Franco R, Bickell NA (2016) Factors affecting the completion of adjuvant chemotherapy in early-stage breast cancer. Ann Surg Oncol 23(5):1537–1542. https://doi.org/10.1245/s10434-015-5039-5

Article  PubMed  Google Scholar 

Samiei S, Simons JM, Engelen SME, Beets-Tan RGH, Classe JM, Smidt ML (2021) Axillary pathologic complete response after neoadjuvant systemic therapy by breast cancer subtype in patients with initially clinically node-positive disease: a systematic review and meta-analysis. JAMA Surg 156(6):e210891. https://doi.org/10.1001/jamasurg.2021.0891